12:00 AM
Feb 25, 2013
 |  BC Week In Review  |  Company News  |  Deals

Cangene, Inspiration Biopharmaceuticals, Ipsen deal

Cangene acquired Inspiration's remaining hemophilia portfolio from Inspiration and partner Ipsen, including nonacog gamma ( IB1001). Cangene will also receive rights to Inspiration's preclinical hemophilia candidates IB1007 and IB1008. Cangene will pay $5.9 million up front and up to $50 million in sales milestones, plus tiered double-digit royalties. Ipsen will receive about 60% of the upfront payment and 80% of other payments.

Cangene also disclosed that FDA...

Read the full 321 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >